A Case Report of Persistent Acinetobacter baumannii Bloodstream Infection

Zhu, Weifeng; Wang, Yang; Wen-xia, Cao; Zhang, Jingping

doi:10.5812/jjm.81946

Cited by 2 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 47 articles were selected for full-text screening. After excluding 31 articles that did not meet the eligibility criteria, a total of 16 articles were finally included for data extraction and analysis [ 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ].…”

Section: Resultsmentioning

confidence: 99%

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Introduction: Acinetobacter baumannii (AB) is a multidrug-resistant pathogen commonly associated with nosocomial infections. The resistance profile and ability to produce biofilm make it a complicated organism to treat effectively. Cefoperazone sulbactam (CS) is commonly used to treat AB, but the associated data are scarce. Methods: We conducted a systematic review of articles downloaded from Cochrane, Embase, PubMed, Scopus, and Web of Science (through June 2022) to study the efficacy of CS in treating AB infections. Our review evaluated patients treated with CS alone and CS in combination with other antibiotics separately. The following outcomes were studied: clinical cure, microbiological cure, and mortality from any cause. Results: We included 16 studies where CS was used for the treatment of AB infections. This included 11 studies where CS was used alone and 10 studies where CS was used in combination. The outcomes were similar in both groups. We found that the pooled clinical cure, microbiological cure, and mortality with CS alone for AB were 70%, 44%, and 20%, respectively. The pooled clinical cure, microbiological cure, and mortality when CS was used in combination with other antibiotics were 72%, 43%, and 21%, respectively. Conclusions: CS alone or in combination needs to be further explored for the treatment of AB infections. There is a need for randomized controlled trials with comparator drugs to evaluate the drug’s effectiveness.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[3][4][5][6] A. baumannii resistance mechanisms refer mainly to the regulation of antibiotic transportation through bacterial membranes, alteration of the antibiotic target site, and enzymatic modifications resulting in antibiotic neutralization. [7] A. baumannii is one of the ESKAPE organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, A. baumannii, Pseudomonas aeruginosa, and Enterobacter spp., [8] and according to the WHO report published in 2017, the ESKAPE group are multidrug-resistant pathogens for which new antibiotics are urgently needed. The WHO's list is categorized into three categories of priority: critical, high, and medium priority, according to the urgency of the need to develop new antibiotics to combat these pathogens.…”

Section: Introductionmentioning

confidence: 99%

“…This gram‐negative bacterium is incredibly resistant to β‐lactam antibiotics (i. e. penicillins, cephalosporins, carbapenems, monobactams, and others (i.e aminoglycosides, tetracyclines, fluoroquinolones, macrolides, lincosamides, streptogramin, polymyxins, amphenicols, oxazolidinones, rifamycins, fosfomycin, and diaminopyrimidine antibiotics) [3–6] . A. baumannii resistance mechanisms refer mainly to the regulation of antibiotic transportation through bacterial membranes, alteration of the antibiotic target site, and enzymatic modifications resulting in antibiotic neutralization [7] . A. baumannii is one of the ESKAPE organisms ( Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia , A. baumannii , Pseudomonas aeruginosa , and Enterobacter spp ., [8] and according to the WHO report published in 2017, the ESKAPE group are multidrug‐resistant pathogens for which new antibiotics are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

Inhibitor Assessment against the LpxC Enzyme of Antibiotic‐resistant Acinetobacter baumannii Using Virtual Screening, Dynamics Simulation, and in vitro Assays

Zoghlami

Oueslati

Basharat

et al. 2022

Molecular Informatics

View full text Add to dashboard Cite

Background: Bacterial resistance is currently a significant global public health problem. Acinetobacter baumannii has been ranked in the list of the World Health Organization as the most critical and priority pathogen for which new antibiotics are urgently needed. In this context, computational methods play a central role in the modern drug discovery process. The purpose of the current study was to identify new potential therapeutic molecules to neutralize MDR A. baumannii bacteria. Methods: A total of 3686 proteins retrieved from the A. baumannii proteome were subjected to subtractive proteomic analysis to narrow down the spectrum of drug targets. The SWISS-MODEL server was used to perform a 3D homology model of the selected target protein. The SAVES server was used to evaluate the overall quality of the model. A dataset of 74500 analogues retrieved from the PubChem database was docked with LpxC using the AutoDock software. Results: In this study, we predicted a putative new inhibitor for the Lpxc enzyme of A. baumannii. The LpxC enzyme was selected as the most appropriate drug target for A. baumannii. According to the virtual screening results, N-[(2S)-3amino-1-(hydroxyamino)-1-oxopropan-2-yl]-4-(4-bromophenyl) benzamide (CS250) could be a promising drug candidate targeting the LpxC enzyme. This molecule shows polar interactions with six amino acids and non-polar interactions with eight other residues. In vitro experimental validation was performed through the inhibition assay. Conclusion:To the best of our knowledge, this is the first study that suggests CS250 as a promising inhibitory molecule that can be exploited to target this gram-negative pathogen.

show abstract

A Case Report of Persistent Acinetobacter baumannii Bloodstream Infection

Cited by 2 publications

References 10 publications

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature

Inhibitor Assessment against the LpxC Enzyme of Antibiotic‐resistant Acinetobacter baumannii Using Virtual Screening, Dynamics Simulation, and in vitro Assays

Contact Info

Product

Resources

About